- Condition Centers
Benazepril HCl Tablets
Marketed by: Amneal Pharmaceuticals (Haupagge, NY)
Compared to: Lotensin (Novartis Pharmaceuticals Corp)
Indication: Amneal Pharmaceuticals recently announced the availability of Benazepril HCl Tablets in strengths of 5, 10, 20, and 40 mg. Benazepril HCl is AB-rated and bioequivalent to the brand product, Lotensin. The tablets are indicated for the treatment of hypertension. It may be used alone or in combination with thiazide diuretics. All 4 strengths of the generic are available in 100- and 500-count sizes.
Dosage Form: Tablets: 5, 10, 20, and 40 mg
For More Information: www.amneal.com
Marketed by: Sandoz (Princeton, NJ)
Compared to: CellCept (Hoffmann-La Roche Inc)
Indication: Sandoz announced the launch of Mycophenolate Mofetil 250-mg capsules and 500-mg tablets. Both are available in 100- and 500-count bottles. Mycophenolate Mofetil is AB-rated to CellCept, and is indicated for the prophylaxis of organ rejection in patients receiving allogeneic renal, cardiac, or hepatic transplants. The product should be used concomitantly with cyclosporine and corticosteroids. Mycophenolate Mofetil has been administered in combination with the following agents in clinical trials: antithymocyte globulin (Atgam), OKT3 (Orthoclone OKT4 3), cyclosporine (Sandimmune, Neoral), and corticosteroids. The efficacy and safety of the use of Mycophenolate Mofetil in combination with other immunosuppressive agents have not been determined.
Dosage Form: Capsules: 250 mg Tablets: 500 mg
For More Information: www.sandoz.com
Pilocarpine HCl Tablets
Marketed by: Lannett Co, Inc (Philadelphia, PA)
Compared to: Salagen (Eisai Pharmaceuticals)
Indication: Lannett Co announced that it received approval from the FDA for its abbreviated new drug application for Pilocarpine HCl Tablets, 7.5 mg. The tablets are indicated for (1) the treatment of symptoms of dry mouth from salivary gland hypofunction caused by radiotherapy for cancer of the head and neck and (2) the treatment of symptoms of dry mouth in patients with Sjogren’s syndrome.
Dosage Form: Tablets: 7.5 mg
For More Information: www.lannett.com
Malathion Lotion 0.5%
Marketed by: Karalex Pharma LLC (Woodcliff Lake, NJ)
Compared to: Ovide (Taro Pharmaceuticals USA Inc)
Indication: Karalex Pharma announced the availability of Malathion Lotion, USP 0.5%, through a licensing agreement with the developers and the holder of the abbreviated new drug application, Synerx Pharma. The lotion is AT-rated and bioequivalent to Ovide. Malathion Lotion 0.5% is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair. The lotion should be applied on dry hair in an amount just sufficient to thoroughly wet the hair and scalp; then, the hair should be allowed to dry naturally; after 8 to 12 hours, the hair should be shampooed and rinsed; then a fine-toothed nit comb should be used to remove dead lice and eggs. If lice are still present after 7 to 9 days, a second application of the lotion should be repeated. Dosage Form: Lotion: 2-fl-oz bottles
For More Information: www.karalexpharma.com 866-306-0240